Advertisement

skin cancer
immunotherapy

PD-1 Inhibitor–Associated Cutaneous Toxicity and Clinical Outcomes in Advanced Melanoma

In a research letter published in JAMA Oncology, Quach et al found that cutaneous toxicities related to anti–programmed cell death protein 1 (PD-1) treatment—specifically, vitiligo and rash—were associated with improved clinical outcomes in advanced melanoma. Study Details The...

health-care policy
cost of care

AMA Commends Final CMS Rule for Requiring Pricing Information in TV Drug Ads

Today, Health and Human Services Secretary Alex Azar announced a final rule from the Centers for Medicare & Medicaid Services (CMS) that will require direct-to-consumer television advertisements for prescription pharmaceuticals covered by Medicare or Medicaid to include the list price—the ...

issues in oncology

WINTHER Trial: Genomic and Transcriptomic Profiling May Translate to New Therapeutic Options for Patients With Advanced Cancer

Published by Rodon et al in Nature Medicine, results of the WINTHER study showed that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial aimed to...

breast cancer

ASBrS 2019: Comprehensive Postoperative Mastectomy Home Recovery Programs Show Patient Benefit

Comprehensive postoperative mastectomy home recovery programs significantly increased same-day patient discharge with no decrease in quality of care, according to two new studies presented at the Annual Meeting of the American Society of Breast Surgeons (ASBrS). “Research demonstrates the...

pain management

Single-Fraction Stereotactic vs Multifraction Radiotherapy for Pain Relief in Predominantly Nonspinal Bone Metastases

In a single-center phase II trial reported in JAMA Oncology, Nguyen et al found that single-fraction stereotactic body radiotherapy (SBRT) was associated with improved pain relief vs conventional multifraction radiotherapy in patients with mostly nonspinal bone metastases. In the noninferiority...

colorectal cancer

Impact of Consensus Molecular Subtype on Outcome in Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Lenz et al found that consensus molecular subtype of colorectal cancers was highly prognostic for outcomes in patients receiving first-line treatment for advanced disease in the phase III CALGB/SWOG 80405/Alliance trial. CALGB/SWOG 80405...

breast cancer

Final Analysis of the HannaH Trial: Perioperative Subcutaneous vs Intravenous Trastuzumab in HER2-Positive Early Breast Cancer

As reported in JAMA Oncology by Jackisch et al, the final analysis of the phase III HannaH trial indicated comparable efficacy and safety of perioperative subcutaneous (SC) vs intravenous (IV) trastuzumab in ERBB2 (HER2)-positive early breast cancer. Earlier reports from the trial showed similar...

bladder cancer

AUA 2019: Studies Highlight Potential Bladder Cancer Risks

Electronic cigarettes (e-cigarettes), exposure to certain environmental factors, and human papillomavirus (HPV) infection may increase the risk of developing bladder cancer, according to new data presented this week at the 2019 Annual Meeting of the American Urological Association (AUA). The...

breast cancer
pain management

ASBrS 2019: Opioid Management Program Reduces Post–Breast Surgery Narcotic Use

A breast surgery opioid prescription management program that analyzed current physician patterns and provided education and guidelines successfully reduced the volume of narcotics given postoperatively to patients at a large institution. These results were presented by Fan et al at the Annual...

breast cancer

ASBrS 2019: Retrospective Study of Nipple-Sparing Mastectomy Outcomes Over Time

Nipple-sparing mastectomy complication and implant failure rates have decreased significantly since introduction of the procedure, while the patient population undergoing nipple-sparing mastectomy increasingly includes more advanced cancers and women traditionally considered at risk for...

symptom management
immunotherapy

Treatment-Related Adverse Events With PD-1/PD-L1 Inhibitors in Clinical Trials

In a systematic review and meta-analysis reported in JAMA Oncology, Wang et al characterized treatment-related adverse event profiles associated with monotherapy use of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors in clinical trials. Study Details...

gynecologic cancer
immunotherapy

GOG-252: Intravenous vs Intraperitoneal Chemotherapy in Advanced Ovarian Carcinoma

In the phase III NRG Oncology/Gynecologic Oncology Group (GOG)-252 study reported in the Journal of Clinical Oncology, Walker et al found no progression-free survival benefit of postsurgical intraperitoneal (IP) chemotherapy vs intravenous (IV) chemotherapy, each combined with bevacizumab, in...

bladder cancer

AUA 2019: OLYMPUS Trial Assesses Mitomycin Gel in Low-Grade Upper Tract Urothelial Carcinoma

Findings from a secondary analysis of the phase III OLYMPUS trial were presented by Kleinmann et al during the Plenary Session at the 2019 American Urological Association (AUA) Annual Meeting (Abstract LBA-16). Results showed that instillation of UGN-101, an investigational formulation of mitomycin ...

prostate cancer

AUA 2019: Insights in Prostate Cancer Identification and Management

Prostate cancer diagnosis and treatment are ever-changing, with new research showcasing different ways to identify and manage patients with the disease. Three new abstracts—highlighting how beta-blockers may impact prostate cancer risk, the advantages and disadvantages of using magnetic...

breast cancer
symptom management

ASBrS 2019: Bioimpedance Spectroscopy for Surveillance of Breast Cancer–Related Lymphedema

Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy. These were the results of an...

breast cancer

ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer

Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....

lung cancer
immunotherapy

Association Between Clinical Outcomes and Patient Characteristics/Genomic Profiles in Lung Cancer

As reported in JAMA, Singal et al used a clinicogenomic database in routine clinical practice to identify associations between treatment outcomes and patient characteristics or tumor genomic profiles in the setting of non–small cell lung cancer (NSCLC). The study cohort of 4,064 patients...

breast cancer

FDA Approves Ado-Trastuzumab Emtansine for HER2-Positive Early Breast Cancer

On May 3, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane- and trastuzumab-based treatment. Patients should be...

breast cancer
prostate cancer
symptom management

ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity

The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...

cns cancers

ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?

A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...

prostate cancer

ESTRO 38: High–Dose Rate Brachytherapy in Localized Prostate Cancer

A single high dose of radiation that can be delivered directly to a treatment site within a few minutes is a safe and effective technique for treating men with localized, low-risk prostate cancer, according to a study presented by Tharmalingam et al at ESTRO 38, the annual congress of the ...

solid tumors
leukemia
prostate cancer
pain management

FDA Pipeline: Applications and Designations in Prostate Cancer, Leukemia, and HER2-Positive Cancers

In the past 2 weeks, the U.S. Food and Drug Administration (FDA) accepted a new drug application and granted Priority Review for a prostate cancer treatment, granted Orphan Drug designation to a treatment for acute lymphoblastic leukemia, accepted an investigational new drug application for a...

gynecologic cancer
cost of care

Treat-and-Release Emergency Department Use by Patients With Gynecologic Cancers

In a study reported in the Journal of Oncology Practice, Albright et al found that treat-and-release emergency department use by patients with gynecologic cancers has increased in recent years, with an increase in total cost in this population but not in average visit cost. Visits and Costs...

leukemia

FDA Approves First-Line Ivosidenib for IDH1-Mutated AML

On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...

lung cancer

ESTRO 38: Radical Hemithoracic Therapy in Patients With Mesothelioma

Patients with mesothelioma are twice as likely to survive for 2 years or longer if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented by Minatel et al at ESTRO 38, the annual congress of the European Society for Radiotherapy...

lymphoma

ESTRO 38: Radiotherapy After ABVD May Improve Survival in Advanced Hodgkin Lymphoma

Patients with advanced Hodgkin lymphoma with bulky lesions at the time of diagnosis may benefit from radiotherapy after chemotherapy, according to late-breaking results presented by Ricardi et al at ESTRO 38, the annual congress of the European Society for Radiotherapy & Oncology...

breast cancer

ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer

Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...

issues in oncology
cost of care
symptom management

Emergency Department Visits for Treatment-Related Complications of Systemic Therapy and Radiotherapy

In a study reported in JAMA Oncology, Jairam et al found that emergency department visits for complications of systemic therapy or radiotherapy in patients with cancer increased at a 5.5-fold higher rate over 10 years compared with overall emergency department visits. Study Details The study...

gynecologic cancer

Adjuvant Pelvic Radiation Therapy vs Vaginal Brachytherapy Plus Chemotherapy in Endometrial Cancer

As reported in the Journal of Clinical Oncology by Randall et al, the phase III Gynecologic Oncology Group (GOG)-0249 trial showed similar outcomes with adjuvant pelvic radiation therapy vs vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial...

colorectal cancer
immunotherapy

IMblaze370: Atezolizumab With or Without Cobimetinib vs Regorafenib in Previously Treated Advanced Colorectal Cancer

In the phase III IMblaze370 trial reported in The Lancet Oncology, Eng et al found no survival benefit with third-line atezolizumab with or without cobimetinib vs regorafenib in patients with locally advanced or metastatic colorectal cancer. Study Details The open-label trial included 363...

breast cancer

ESMO Breast Cancer 2019: Does Continuous Chemotherapy Benefit Patients With Advanced Breast Cancer?

Continuous chemotherapy showed greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented by Erdkamp et al and Claessens et al at the European...

breast cancer

ESMO Breast Cancer 2019: PERNETTA Trial Examines Treatment De-escalation in Women With HER2-Positive Breast Cancer

De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to a European Society for Medical Oncology (ESMO) spokesperson Carmen Criscitiello, MD, PhD, of the European Institute of Oncology in Milan, Italy. Dr. Criscitello commented on the ...

lung cancer
issues in oncology

Survey Finds Rates of Physician-Patient Discussions About Lung Cancer Screening Are Declining

A study examining trends in patient-reported physician-patient discussions about lung cancer screening and the association of these discussions with smokers’ attempts to quit and intent to quit has found that discussions about screening have declined since 2012. Moreover, they were not...

hepatobiliary cancer

Minimal Adjuvant Chemotherapy for Pediatric Hepatoblastoma Resected at Diagnosis

In an analysis from the Children’s Oncology Group phase III AHEP0731 trial reported in The Lancet Oncology, Katzenstein et al found that minimal adjuvant chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine was associated with disease control in pediatric patients with...

leukemia

Long-Term Follow-up: Addition of Idelalisib to Rituximab in Relapsed Chronic Lymphocytic Leukemia

In an article published in the Journal of Clinical Oncology, Sharman et al provided long-term findings of a phase III trial that examined the addition of idelalisib to rituximab in relapsed chronic lymphocytic leukemia (CLL), including findings from an extension phase of idelalisib monotherapy. The ...

breast cancer

ESMO Breast Cancer 2019: Outcomes in Younger Patients With Breast Cancer

Breast cancer in young women is characterized by more aggressive biologic features as compared to older patients, but outcomes are good when guideline-recommended treatments are given. European Society for Medical Oncology (ESMO) spokesperson Matteo Lambertini, MD, PhD, of IRCCS Policlinico San...

breast cancer

ESMO Breast Cancer 2019: Evidence-Based Educational Nutrition Intervention Among Patients With Early-Stage Breast Cancer

Although tools like the ESPEN guidelines on nutrition for patients with cancer have helped to standardize practices in this area of patient care, scientific evidence on the efficacy of nutritional intervention among patients with breast cancer is still scarce. Preliminary results from a study to be ...

breast cancer
issues in oncology
global cancer care

ESMO Breast Cancer 2019: ONCOLLEGE-001: Global Survey of HER2 Testing

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2-targeted therapies for breast cancer, especially in lower-income countries. These results will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer...

prostate cancer

Final Overall Survival Analysis of the LATITUDE Trial in Newly Diagnosed, High-Risk, Metastatic, Castration-Sensitive Prostate Cancer

As reported in The Lancet Oncology by Fizazi et al, the final overall survival analysis in the phase III LATITUDE trial has shown a significant benefit with the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) in newly diagnosed, high-risk, metastatic, ...

sarcoma

Phase II Study of Regorafenib in Metastatic Osteosarcoma

As reported in the Journal of Clinical Oncology by Davis et al, outcomes in the osteosarcoma cohort of the phase II SARC024 trial indicated a progression-free survival benefit with regorafenib vs placebo in previously treated metastatic osteosarcoma. Study Details The randomized...

colorectal cancer

Colon Cancer Proteogenomic Analysis May Uncover New Potential Treatments

A new study analyzing the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor, pointing to novel cancer biologic mechanisms and possible new therapeutic strategies. This multidisciplinary and...

symptom management

New Biomarkers Associated With Cancer-Related Cognitive Impairment Identified

Cognitive impairment associated with cancer—also known as “chemobrain”—has gained recognition as a complication of the disease and its treatment. With this in mind, a research team started to investigate levels of biomarkers in relation to chemobrain to better understand its ...

breast cancer

Study Identifies Six Prognostic Factors That May Predict Invasive Breast Cancer Recurrence After a DCIS Diagnosis

Results from a new study are providing information to potentially improve the clinical management of women diagnosed with ductal carcinoma in situ (DCIS). A systematic review with meta-analyses to summarize current knowledge on prognostic factors for invasive disease after a diagnosis of DCIS has...

lung cancer

Erlotinib Plus Bevacizumab vs Erlotinib Alone in EGFR-Positive, Advanced Nonsquamous NSCLC

In an interim analysis of the phase III NEJ026 trial reported in The Lancet Oncology, Saito et al found that the addition of bevacizumab to erlotinib improved progression-free survival in patients with EGFR-positive, nonsquamous non–small cell lung cancer (NSCLC). In the open-label...

hematologic malignancies
lymphoma

Risk Model for Disease Progression in Asymptomatic Waldenström’s Macroglobulinemia

In a study reported in the Journal of Clinical Oncology, Bustoros et al developed a model for predicting risk of progression from asymptomatic Waldenström’s macroglobulinemia to symptomatic disease requiring treatment. The study involved 439 patients with asymptomatic...

hepatobiliary cancer

Addition of Nab-paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancers

In a phase II trial reported in JAMA Oncology, Shroff and colleagues found that the addition of nab-paclitaxel to standard gemcitabine and cisplatin resulted in promising outcomes in patients with unresectable locally advanced or metastatic biliary tract cancers. The study included 60 patients...

leukemia

Intermittent vs Intensive PEG-Asparaginase in Pediatric Acute Lymphoblastic Leukemia

In a Scandinavian study reported in the Journal of Clinical Oncology, Albertsen et al found that use of intermittent vs intensive pegylated (PEG)-asparaginase was associated with similar efficacy and reduced asparaginase-related toxicity in pediatric acute lymphoblastic leukemia (ALL). The study...

Joe Biden and Dr. Jill Biden Step Down From Biden Cancer Initiative Board

In light of the launch of his campaign for the 2020 Democratic presidential nomination, former Vice President Joe Biden and Dr. Jill Biden announced that they are stepping down as Co-Chairs of the Biden Cancer Initiative. They are also resigning from the Board of Directors. “[W]e are glad...

sarcoma

Access Program to Be Established for Patients After Olaratumab Is Withdrawn From the Global Market

On April 25, Eli Lilly and Company announced that the company has been working to facilitate the withdrawal of olaratumab from the market for the treatment of advanced soft-tissue sarcoma. Lilly's actions to withdraw olaratumab from the market follow completion of the international phase III...

health-care policy
hematologic malignancies
immunotherapy

ASH President Comments on Medicare Proposal for CAR T-Cell Therapy

Earlier this week, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor T-cell (CAR-T) therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment...

Advertisement

Advertisement



Advertisement